NCT01266083 2024-11-19
WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)
Sellas Life Sciences Group
Phase 2 Completed
Clinical Trials
11 trialsNCT03761914 2024-11-19
Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Sellas Life Sciences Group
Phase 1/2 Completed
NCT01265433 2024-10-09
Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy
Sellas Life Sciences Group
Phase 2 Completed
NCT01827137 2024-09-19
WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation
Sellas Life Sciences Group
Phase 1/2 Completed
NCT00616941 2022-10-12
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ludwig Institute for Cancer Research
Phase 1 Completed
NCT00112242 2020-06-18
Immunotherapy of Stage III/IV Melanoma Patients
Centre Hospitalier Universitaire Vaudois
Phase 1 Completed
NCT01079741 2018-02-13
Safety Study of Adjuvant Vaccine to Treat Melanoma Patients
Icahn School of Medicine at Mount Sinai
Phase 1/2 Completed
NCT00935545 2016-01-26
Study of Peptide Vaccination With Tumor Associated Antigens Mixed With Montanide in Patients With CNS Tumors
NYU Langone Health
Phase 1 Completed
NCT00665002 2015-02-27
Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms
H. Lee Moffitt Cancer Center and Research Institute
Phase NA Completed
NCT00124124 2015-02-13
Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine
Bhardwaj, Nina, M.D.
Phase 1 Completed
NCT00651703 2010-11-15
Safety and Immunogenicity of CYT004-MelQbG10 Vaccine With and Without Adjuvant in Advanced Stage Melanoma Patients
Cytos Biotechnology AG
Phase 2 Completed